Your browser doesn't support javascript.
loading
Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
Nowak, Natalia; Skupien, Jan; Smiles, Adam M; Yamanouchi, Masayuki; Niewczas, Monika A; Galecki, Andrzej T; Duffin, Kevin L; Breyer, Matthew D; Pullen, Nick; Bonventre, Joseph V; Krolewski, Andrzej S.
Afiliação
  • Nowak N; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.
  • Skupien J; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland. Electronic address: Jan
  • Smiles AM; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA.
  • Yamanouchi M; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Niewczas MA; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Galecki AT; Institute of Gerontology, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Duffin KL; Lilly Research Laboratories, Eli Lilly & Company Inc. Corporate Center Indianapolis, Indiana, USA.
  • Breyer MD; Lilly Research Laboratories, Eli Lilly & Company Inc. Corporate Center Indianapolis, Indiana, USA.
  • Pullen N; Pfizer Inc., 610 Main Street, Cambridge, Massachusetts, USA.
  • Bonventre JV; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; Renal Division, Brigham & Women Hospital, Boston, Massachusetts, USA.
  • Krolewski AS; Section on Genetics and Epidemiology, Research Divisions, Joslin Diabetes Center, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: Andrzej.krolewski@joslin.harvard.edu.
Kidney Int ; 93(5): 1198-1206, 2018 05.
Article em En | MEDLINE | ID: mdl-29398132
ABSTRACT
To identify determinants of early progressive renal decline in type 2 diabetes a range of markers was studied in 1032 patients enrolled into the 2nd Joslin Kidney Study. eGFR slopes estimated from serial measurements of serum creatinine during 5-12 years of follow-up were used to define early renal decline. At enrollment, all patients had normal eGFR, 58% had normoalbuminuria and 42% had albuminuria. Early renal decline developed in 6% and in 18% patients, respectively. As determinants, we examined baseline values of clinical characteristics, circulating markers TNFR1, KIM-1, and FGF23, and urinary markers albumin, KIM-1, NGAL, MCP-1, EGF (all normalized to urinary creatinine) and the ratio of EGF to MCP-1. In univariate analysis, all plasma and urinary markers were significantly associated with risk of early renal decline. When analyzed together, systolic blood pressure, TNFR1, KIM-1, the albumin to creatinine ratio, and the EGF/MCP-1 ratio remained significant with the latter having the strongest effect. Integration of these markers into a multi-marker prognostic test resulted in a significant improvement of discriminatory performance of risk prediction of early renal decline, compared with the albumin to creatinine ratio and systolic blood pressure alone. However, the positive predictive value was only 50% in albuminuric patients. Thus, markers in plasma and urine indicate that the early progressive renal decline in Type 2 diabetes has multiple determinants with strong evidence for involvement of tubular damage. However, new, more informative markers are needed to develop a better prognostic test for such decline that can be used in a clinical setting.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biomarcadores / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article